Claims

[Claim 1]. Use of a nucleotide composition, for the manufacture of a medicament for promoting reparation of enterocytes after damage caused by oxidation, wherein the nucleotide composition consists of CMP, AMP, UMP and GMP, and the proportions of each of the nucleotides, on a weight basis relative to the total weight of the nucleotide composition, are CMP: 58-72%, AMP: 6-14%, UMP: 10-18% and GMP: 8-14%, provided that sum of the proportions is 100%.

[Claim 2]. The use according to claim 1, wherein the proportions of the components of the nucleotide composition are CMP: 60-70%, AMP: 8-12%, UMP: 12-16% and GMP: 10-12%.

[Claim 3]. The use according to claim 1, wherein the proportions of the components of the nucleotide composition are CMP: 60-65%, AMP: 10-12%, UMP: 14-16% and GMP: 11-12%.

[Claim 4]. The use according to claim 1, wherein the proportions of the components of the nucleotide composition are CMP: 65-70%, AMP: 8-10%, UMP: 12-14% and GMP: 10-11%.

[Claim 5]. The use according to claim 1, wherein the proportions of the components of the nucleotide composition are

CMP: 60%, AMP: 12%, UMP: 16% and GMP: 12%;
CMP: 65%, AMP: 10%, UMP: 14% and GMP: 11%; or
CMP: 70%, AMP: 8%, UMP: 12% and GMP: 10%.